Stoughton, MA, United States of America

Meir Glick




Average Co-Inventor Count = 2.0

ph-index = 4

Forward Citations = 186(Granted Patents)


Location History:

  • Stoughton, MA (US) (2008 - 2009)
  • Morristown, NJ (US) (2010)
  • Staughton, MA (US) (2010)

Company Filing History:


Years Active: 2008-2010

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Meir Glick: Innovator in T Cell Receptor Technology

Introduction

Meir Glick is a notable inventor based in Stoughton, MA (US), recognized for his contributions to the field of immunology. He holds a total of five patents, showcasing his innovative approach to T cell receptor technology. His work has significant implications for therapeutic applications in immunology and cancer treatment.

Latest Patents

Glick's latest patents include advancements in soluble T cell receptors (sTCR). One of his inventions provides a soluble T cell receptor that comprises all or part of a TCR α chain and a TCR β chain, excluding the transmembrane domain. Each component includes a functional variable domain and part of the constant domain, linked by a disulfide bond not found in native TCRs. Another patent focuses on a modified soluble T cell receptor that recognizes a CD1-antigen complex, a bacterial superantigen, or a peptide-MHC/superantigen complex, further enhancing the potential for targeted immunotherapy.

Career Highlights

Throughout his career, Meir Glick has worked with prominent companies in the biotechnology sector, including Immunocore Limited and Medigene, Inc. His experience in these organizations has allowed him to refine his expertise in T cell receptor technology and contribute to groundbreaking research.

Collaborations

Glick has collaborated with various professionals in the field, including Bent Karsten Jakobsen, enhancing the scope and impact of his research.

Conclusion

Meir Glick's innovative work in T cell receptor technology has positioned him as a key figure in immunology. His patents reflect a commitment to advancing therapeutic strategies that could significantly benefit patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…